Equities research analysts expect Chimerix, Inc. (NASDAQ:CMRX – Get Rating) to announce earnings of ($0.35) per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Chimerix’s earnings. The lowest EPS estimate is ($0.40) and the highest is ($0.23). Chimerix reported earnings per share of ($0.18) during the same quarter last year, which indicates a negative year-over-year growth rate of 94.4%. The firm is scheduled to issue its next quarterly earnings results on Monday, January 1st.
According to Zacks, analysts expect that Chimerix will report full year earnings of ($0.15) per share for the current year, with EPS estimates ranging from ($0.27) to ($0.01). For the next financial year, analysts anticipate that the business will report earnings of ($0.06) per share, with EPS estimates ranging from ($0.25) to $0.16. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that cover Chimerix.
Chimerix (NASDAQ:CMRX – Get Rating) last announced its earnings results on Tuesday, March 1st. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.34). The business had revenue of $0.05 million for the quarter, compared to the consensus estimate of $45.06 million. Chimerix had a negative net margin of 8,753.71% and a negative return on equity of 84.90%. During the same period in the previous year, the firm earned ($0.19) EPS.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Chimerix by 38.1% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,753 shares of the biopharmaceutical company’s stock valued at $81,000 after buying an additional 4,894 shares during the period. Joel Isaacson & Co. LLC bought a new position in shares of Chimerix in the 1st quarter worth $152,000. Barclays PLC boosted its position in shares of Chimerix by 192.6% in the 4th quarter. Barclays PLC now owns 88,606 shares of the biopharmaceutical company’s stock worth $570,000 after purchasing an additional 58,325 shares during the last quarter. BlackRock Inc. boosted its position in shares of Chimerix by 9.1% in the 4th quarter. BlackRock Inc. now owns 5,381,236 shares of the biopharmaceutical company’s stock worth $34,602,000 after purchasing an additional 447,818 shares during the last quarter. Finally, California State Teachers Retirement System boosted its position in shares of Chimerix by 2.6% in the 4th quarter. California State Teachers Retirement System now owns 101,758 shares of the biopharmaceutical company’s stock worth $654,000 after purchasing an additional 2,572 shares during the last quarter. 62.76% of the stock is owned by institutional investors.
Shares of NASDAQ CMRX opened at $4.70 on Tuesday. The business’s 50-day moving average price is $5.07 and its two-hundred day moving average price is $5.64. Chimerix has a one year low of $3.34 and a one year high of $9.29. The company has a market capitalization of $409.04 million, a P/E ratio of -2.26 and a beta of 1.28.
About Chimerix (Get Rating)
Chimerix, Inc, a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox.
- Get a free copy of the StockNews.com research report on Chimerix (CMRX)
- Tractor Supply Stock Should Plow Ahead
- MarketBeat Podcast: Investing In Innovation, Robotics, AI and Healthcare
- GitLab Stock is Trying to Put in a Bottom Here
- It’s Time to Book an Appointment for Teladoc Stock
- Saia Growth Accelerates But It May Not Matter
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.